Cantor Fitzgerald Initiates Coverage On Madrigal Pharmaceuticals with Neutral Rating
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has initiated coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral rating by analyst Prakhar Agrawal.
June 28, 2024 | 11:47 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has initiated coverage on Madrigal Pharmaceuticals with a Neutral rating, indicating a balanced view on the stock's potential.
The Neutral rating suggests that the analyst sees neither significant upside nor downside in the short term for Madrigal Pharmaceuticals. This balanced view is likely to result in minimal immediate impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100